Journal · Updated 2026-08-11
Mississippi Medicaid and GLP-1s in 2026: Covered With PA — and the Expansion Bill the Governor Vetoed Without Touching Existing Coverage
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Mississippi covers GLP-1 medications for weight loss under Medicaid — Wegovy, Zepbound, and Saxenda, with prior authorization — and appears on every major 2026 covering-state count. The state's 2026 legislative story is the mirror image of Minnesota's: where Minnesota saw a bill to end coverage get delayed, Mississippi saw a bill to expand it — SB 2867 — pass the legislature and die by governor's veto on fiscal-concern grounds, with existing coverage continuing unchanged. The distinction is the whole point: a vetoed expansion is not a cut, and readers who saw a "GLP-1 bill vetoed in Mississippi" headline and assumed the benefit ended assumed wrong. The covered baseline stands.
The veto, read correctly
The tracker record is specific: SB 2867 would have expanded the existing benefit; the governor's veto cited fiscal concerns; and the operative clause for enrollees is "existing coverage continues." Two lessons ride on that clause. First, headline risk runs both directions in this policy area — the change ledger exists because "state GLP-1 bill fails" can mean expansion blocked, restriction blocked, or coverage ended, and only the dated record distinguishes them. Second, a fiscal-concern veto of an expansion is a weather report: it tells you where the budget pressure sits when Mississippi's benefit next comes up for review. The rational enrollee response is the same annual re-check this site recommends in every covering state, with slightly more attention to the state's budget session.
Using the coverage, and the doors beyond it
The PA package runs the standard covering-state course — documented BMI at the program threshold, comorbidities where required, lifestyle-attempt evidence, the PA guide's checklist — with the managed-care layer's plan-specific forms on top; our review verifies the three-drug list and the PA requirement but no Mississippi-specific published threshold, so the current criteria come from the Division of Medicaid or your plan's pharmacy line, not from any summary including this one. Beyond the weight-loss indication: the federally required diabetes door, the cardiovascular, sleep-apnea, kidney, and MASH doors per the playbook, the under-21 EPSDT path, and the cash floor — compounded semaglutide near one hundred dollars a month, tirzepatide under one hundred seventy on current promotional cards, with the verification homework attached. National context at the Medicaid hub.
Questions people ask
Does Mississippi Medicaid cover Wegovy or Zepbound for weight loss in 2026?
Yes — Wegovy, Zepbound, and Saxenda with prior authorization, per every major 2026 covering-state count. The 2026 veto of SB 2867 blocked an expansion of the benefit; it did not touch existing coverage, which continues.
Didn't the governor veto a GLP-1 bill? What actually happened?
SB 2867 would have expanded Mississippi's existing GLP-1 coverage; the governor vetoed it citing fiscal concerns, and the tracker record states explicitly that existing coverage continues. A blocked expansion is not a cut — the distinction most headlines blurred.
What does Mississippi's prior authorization require?
The trackers verify PA is required; no Mississippi-specific published threshold appears in our sources, so get the current criteria from the Division of Medicaid or your managed-care plan's pharmacy line before submitting. Expect the standard package: BMI documentation, comorbidities where applicable, lifestyle-attempt evidence.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.